医学
药物开发
先天免疫系统
获得性免疫系统
免疫系统
疾病
重症监护医学
免疫
药品
免疫学
钥匙(锁)
药物发现
小分子
炎症
生物信息学
药理学
计算生物学
髓系细胞
药品管理局
神经科学
作者
Veronica Batani,Jelena Colic,Cristina Scaletti,Raffaella Molteni,Giacomo Davide De Luca,Giulia Bandini,Lorenzo Dagna,Francesco Annunziato,Marco Matucci‐Cerinic,Corrado Campochiaro
标识
DOI:10.1080/1744666x.2026.2636654
摘要
INTRODUCTION: Systemic sclerosis (SSc) is increasingly understood as a triad of immune dysregulation, progressive fibrosis, and vasculopathy that evolve in parallel. The literature search was conducted using PubMed/MEDLINE, ClinicalTrials.gov, and the European Clinical Trials Database (EudraCT), including studies published in English up to October 2025. AREAS COVERED: This review summarizes the most recent therapeutic strategies now in clinical development and links each to its underpinning pre‑clinical and translational evidence, thereby mapping how mechanistic insights are reshaping drug pipeline in SSc. EXPERT OPINION: A key breakthrough is the emergence of cell‑based immunotherapies, bispecific antibodies, and next‑generation small molecules that extend beyond adaptive immune targets to modulate innate immunity directly. Collectively, these agents illustrate a unifying concept: successful disease modification will require the synchronous interception of inflammation, fibrotic remodeling, and vascular injury rather than approaching these domains independently.
科研通智能强力驱动
Strongly Powered by AbleSci AI